doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_base_np	arg_protein	arg_domain	arg_site	arg_sugar	PSource	SiteSource	NProtein	NID	SiteName	sent_text
31355147	8	66	gly	sialylated	1617:1626	arg1	sialylated N-glycans				sialylated N-glycans						Among these, six N-glycans were modified with sialic acid or fucose based on LacNAc to form sialylated N-glycans or lewis antigens, respectively.
31099376	11	0	gly	composition	1861:1871	arg1	carbohydrate surfaces			position	carbohydrate surfaces					position	The selection and positioning of sugars within a glycan shield can influence how carbohydrate surfaces of different composition adhere.
30919164	1	6	gly	acids	267:271	arg1	serine			glycine, phenylalanine, and serine						glycine, phenylalanine, and serine	The physical and structural stability of freeze-dried immunoglobulin G (IgG) were examined by applying trehalose and amino acids (glycine, phenylalanine, and serine).
30258536	7	16	gly	glycosylated	1931:1942	arg1	aberrantly glycosylated IgG Fc variants	aberrantly glycosylated IgG Fc variants				Fterm		variants			The results suggest that aberrantly glycosylated IgG Fc variants may contribute to the total biological activities of the therapeutic antibodies.
35518704	3	35	gly	glycoproteins	702:714	arg1	therapeutic glycoproteins	therapeutic glycoproteins				Fterm		glycoproteins			In the present study, we genetically manipulated O-glycosylation by disrupting O-mannosyltransferase PMT1 and PMT5 in a low-mannose type N-linked oligosaccharide (Man12GlcNAc2∼Man16GlcNAc2) engineered Pichia pastoris strain to produce therapeutic glycoproteins.
30910957	5	8	gly	glycosite	848:856	arg2	glycosite mapping			glycosite mapping						glycosite	We exploited StcE's unique properties to improve sequence coverage, glycosite mapping, and glycoform analysis of recombinant human mucins by mass spectrometry.
30997002	2	45	gly	deglycosylated	439:452	arg1	glycan				glycan						Each mAb is examined in three states; glycan intact, truncated (following endoS2 treatment) and fully deglycosylated.
30426864	3	49	gly	used	426:429	arg2	calcitonin gene-related peptide			calcitonin gene-related peptide						peptide	Naringin and calcitonin gene-related peptide were used as drugs to prepare drug-loaded scaffolds by direct printing or surface absorption.
31276140	3	7	gly	glycosylated	492:503	arg1	glycosylated hemoglobin	glycosylated hemoglobin				Fterm		hemoglobin			The administration of PAS in diabetic mice caused a significant decrease in the glucose level and serum levels of glycosylated hemoglobin (HbA1c).
29351237	9	2	gly	O-fucosylated	1124:1136	arg1	Ser60			Ser60				Factor VIIa		Ser60	Ser60 was found to be O-fucosylated and Ser52 had O-glucose or O-glucose-(xylose)1,2 motifs as glycan variants.
29351237	9	1	gly	had	1148:1150	arg1	Ser52 AND glycan variants			Ser52	glycan variants			Factor VIIa		Ser52	Ser60 was found to be O-fucosylated and Ser52 had O-glucose or O-glucose-(xylose)1,2 motifs as glycan variants.
29351237	9	1	gly	had	1148:1150	arg1	Ser52 AND xylose			Ser52	xylose			Factor VIIa		Ser52	Ser60 was found to be O-fucosylated and Ser52 had O-glucose or O-glucose-(xylose)1,2 motifs as glycan variants.
29351237	9	1	gly	had	1148:1150	arg1	Ser52 AND O-glucose-			Ser52	O-glucose-			Factor VIIa		Ser52	Ser60 was found to be O-fucosylated and Ser52 had O-glucose or O-glucose-(xylose)1,2 motifs as glycan variants.
29351237	9	1	gly	had	1148:1150	arg1	Ser52 AND O-glucose			Ser52	O-glucose			Factor VIIa		Ser52	Ser60 was found to be O-fucosylated and Ser52 had O-glucose or O-glucose-(xylose)1,2 motifs as glycan variants.
31581071	7	12	gly	glycoprotein	1172:1183	arg1	Carcinoembryonic antigen	Carcinoembryonic antigen				PUBTATOR		Carcinoembryonic antigen	1084		Carcinoembryonic antigen (CEA), a routinely used marker for colon cancer, was used as a test glycoprotein.
31581071	7	12	gly	glycoprotein	1172:1183	arg1	a test glycoprotein	a test glycoprotein				Fterm		glycoprotein			Carcinoembryonic antigen (CEA), a routinely used marker for colon cancer, was used as a test glycoprotein.
30087707	8	36	gly	structures	1127:1136	arg1	β1-integrin	1-integrin			structures	PUBTATOR		1-integrin	3688		Mechanistic investigations showed that C1GalT1 modified O-glycan structures on β1-integrin and regulated its downstream focal adhesion kinase (FAK) signaling.
29673061	7	67	gly	contained	1298:1306	arg1	the NP region AND 313.40 ± 50.67 µg/mg glycosaminoglycan			the NP region	313.40 ± 50.67 µg/mg glycosaminoglycan					region	Moreover, the NP region of decellularized IVDs contained 313.40 ± 50.67 µg/mg glycosaminoglycan.
30553356	9	23	gly	used	1385:1388	arg2	modified MMTs-BC nanocomposites			modified MMTs-BC nanocomposites						nanocomposites	These findings demonstrated that modified MMTs-BC nanocomposites could be used as a novel artificial skin substitute for burn patients and scaffold for skin tissue engineering.
31581071	0	59	gly	glycoproteins	155:167	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Orthogonal dual molecularly imprinted polymer-based plasmonic immunosandwich assay: A double characteristic recognition strategy for specific detection of glycoproteins.
31687435	4	25	gly	glycoproteins	938:950	arg1	tissue glycoproteins	tissue glycoproteins				Fterm		glycoproteins			An enzyme-linked immunosorbent assay using an anti-α2,6-sialyl LacNAc antibody also supported this result, indicating that dietary carbohydrate restriction results in aberrant glycosylation of tissue glycoproteins.
31687435	4	27	gly	glycosylation	914:926	arg1	tissue glycoproteins	tissue glycoproteins				Fterm		glycoproteins			An enzyme-linked immunosorbent assay using an anti-α2,6-sialyl LacNAc antibody also supported this result, indicating that dietary carbohydrate restriction results in aberrant glycosylation of tissue glycoproteins.
31200599	7	48	gly	glycoproteins	1317:1329	arg1	ECM glycoproteins	ECM glycoproteins				OGER		ECM glycoproteins	Q13201		This method was compared with a well-established label-free quantification (LFQ) approach which rendered similar expressions of different categories of proteins (collagens, ECM glycoproteins, proteoglycans, etc.).
31307013	5	37	gly	N347	1021:1024	arg1	an N-glycan			N347	an N-glycan			corticosteroid-binding globulin	866	N347	RESULTS We demonstrate that an N-glycan at N347 within the CBG RCL limits the 9G12 antibody from recognizing its epitope, whereas the 12G2 antibody reactivity is unaffected, thereby contributing to discrepancies in ELISA measurements using these two antibodies.
29865036	5	24	gly	proteins	801:808	arg1	N-	proteins			N-	Fterm		proteins			METHODS We used Aleuria Aurantia Lectin (AAL)-magnetic particle conjugates to isolate fucosylated glycoproteins in the pooled saliva of healthy volunteers (HV, n= 51) and patients with atrophic gastritis (AG, n= 51) or GC (n= 51), following to release the N- and O-linked glycans from the isolated proteins with PNGase F and NaClO, and further identified the released glycans by MALDI-TOF/TOF-MS, respectively.
29865036	5	24	gly	proteins	801:808	arg1	O-linked glycans	proteins			O-linked glycans	Fterm		proteins			METHODS We used Aleuria Aurantia Lectin (AAL)-magnetic particle conjugates to isolate fucosylated glycoproteins in the pooled saliva of healthy volunteers (HV, n= 51) and patients with atrophic gastritis (AG, n= 51) or GC (n= 51), following to release the N- and O-linked glycans from the isolated proteins with PNGase F and NaClO, and further identified the released glycans by MALDI-TOF/TOF-MS, respectively.
29865036	5	56	gly	fucosylated	589:599	arg1	fucosylated glycoproteins	fucosylated glycoproteins				Fterm		glycoproteins			METHODS We used Aleuria Aurantia Lectin (AAL)-magnetic particle conjugates to isolate fucosylated glycoproteins in the pooled saliva of healthy volunteers (HV, n= 51) and patients with atrophic gastritis (AG, n= 51) or GC (n= 51), following to release the N- and O-linked glycans from the isolated proteins with PNGase F and NaClO, and further identified the released glycans by MALDI-TOF/TOF-MS, respectively.
29865036	5	105	gly	glycoproteins	601:613	arg1	fucosylated glycoproteins	fucosylated glycoproteins				Fterm		glycoproteins			METHODS We used Aleuria Aurantia Lectin (AAL)-magnetic particle conjugates to isolate fucosylated glycoproteins in the pooled saliva of healthy volunteers (HV, n= 51) and patients with atrophic gastritis (AG, n= 51) or GC (n= 51), following to release the N- and O-linked glycans from the isolated proteins with PNGase F and NaClO, and further identified the released glycans by MALDI-TOF/TOF-MS, respectively.
34123048	5	0	gly	sialylated	1066:1075	arg1	sialylated glycan linkage isomers				sialylated glycan linkage isomers						Importantly, different "OFF-ON" ratios of the conical nanochannels system allows the precise and sensitive discrimination of sialylated glycan linkage isomers, α2-3 and α2-6 linkage (the corresponding ion conductance increase ratios are 96.2% and 264%, respectively).
31236201	6	2	gly	glycoproteins	989:1001	arg1	an enhanced EV glycoproteins detection	an enhanced EV glycoproteins detection				Fterm		glycoproteins			In addition, ODG and SEC isolation protocols provided an enhanced EV glycoproteins detection.
30501912	2	69	gly	content	529:535	arg1	ECM	ECM			content	OGER		ECM	Q13201		Depth-dependent proteoglycan (PG) content, collagen content and collagen orientation in the cartilage extracellular matrix (ECM), and PG content in the pericellular matrix (PCM) were assessed with microscopic and spectroscopic methods.
29420149	4	62	gly	arm	891:893	arg1	leg				leg						Muscle glycogen content using 13C-magnetic resonance spectroscopy, blood hydration status, body composition, and ECW and ICW content of the arm, trunk, and leg using BIS were measured.
30385318	4	12	gly	deglycosylated	468:481	arg1	human BChE	human BChE				PUBTATOR		BChE	590		Although the X-ray structure of a partially deglycosylated monomer of human BChE was solved 15 years ago, all attempts to determine the 3D structure of the natural full-length glycosylated tetrameric human BChE have been unsuccessful so far.
30385318	4	61	gly	glycosylated	600:611	arg1	the natural full-length glycosylated tetrameric human BChE	the natural full-length glycosylated tetrameric human BChE				PUBTATOR		BChE	590		Although the X-ray structure of a partially deglycosylated monomer of human BChE was solved 15 years ago, all attempts to determine the 3D structure of the natural full-length glycosylated tetrameric human BChE have been unsuccessful so far.
30258536	5	62	gly	carrying	1439:1446	arg1	Fc nonapeptide AND a GlcNAc			Fc nonapeptide	a GlcNAc					nonapeptide	Use of a key intermediate, phenyl (2-O-benzyl-4,6-O-benzylidine-β-d-mannopyranosyl)-(1 → 4)-3,6-di-O-benzyl-2-azido-2-deoxy-1-thio-β-d-glucopyranoside, derived from locust bean gum galactomannan, facilitated greatly the synthesis of a bisected nonasaccharide as a stable precursor of oxazoline derivative needed for the enzymatic trans-glycosylation with Fc nonapeptide carrying a GlcNAc at Asn297 residue, while the coupling reaction catalyzed by mutant endo-M-N175Q proceeded very slowly.
31892045	3	11	gly	used	458:461	arg2	The magG@Zn-MOFs composites			The magG@Zn-MOFs composites						composites	The magG@Zn-MOFs composites were used for extraction of acarbose in plasma prior to its quantitative analysis by LC-MS/MS.
31307013	6	4	gly	N-glycosylation	1267:1281	arg1	N238			N238				corticosteroid-binding globulin	866	N238	Qualitative differences in N-glycosylation at N238 also negatively affect the steroid-binding of CBG in the absence of an N-glycan at N347 caused by a T349A substitution.
31016304	9	9	gly	enoxaparin	1451:1460	arg1	the glycan size distribution	enoxaparin			the glycan size distribution	Fterm		enoxaparin			The results showed that the glycan size distribution of an enoxaparin is more related to its production process.
29432186	3	31	gly	N-glycosylation	440:454	arg2	consensus amino acid motifs			consensus amino acid motifs						motifs	However, variable domains may also acquire N-linked glycans, a process conditional on the introduction of consensus amino acid motifs (N-glycosylation sites) during somatic hypermutation.
29432186	3	31	gly	N-glycosylation	440:454	arg2	N-glycosylation sites			N-glycosylation sites						sites	However, variable domains may also acquire N-linked glycans, a process conditional on the introduction of consensus amino acid motifs (N-glycosylation sites) during somatic hypermutation.
29432186	0	42	gly	glycosylation	51:63	arg1	the immunoglobulin variable region			the immunoglobulin variable region						region	Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.
30030075	4	9	gly	used	700:703	arg2	their composites			their composites						composites	The obtained Biodegradable grafted cellulose and their composites were used as adsorbents for the removal of Ca, Mg, Fe, Pb, and Cu ions individually from aqueous solutions.
30258536	1	107	gly	attached	126:133	arg1	the IgG Fc domain AND Glycans			the IgG Fc domain	Glycans					domain	Glycans attached to the IgG Fc domain affect strongly biological activities such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) of therapeutic antibodies.
30884009	2	67	gly	used	225:228	arg2	These antibiotic peptides			These antibiotic peptides						peptides	These antibiotic peptides can be used to prevent infections in agriculture and food industry but also to prepare antimicrobial lozenges, creams, and dressings for medical applications.
31792963	4	39	gly	cartilage	791:799	arg1	the tendon relevant genes collagen type 1 (Col1)	cartilage oligomeric matrix protein			the tendon relevant genes collagen type 1 (Col1)	OGER		cartilage oligomeric matrix protein	P49747		Age-related differences in the distribution pattern of tendon fibril thickness and in the expression of the tendon relevant genes collagen type 1 (Col1), Col3, Col5, tenascin-C, decorin, tenomodulin, versican, scleraxis and cartilage oligomeric matrix protein were investigated.
31792963	4	43	gly	matrix	812:817	arg1	the tendon relevant genes collagen type 1 (Col1)	cartilage oligomeric matrix protein			the tendon relevant genes collagen type 1 (Col1)	OGER		cartilage oligomeric matrix protein	P49747		Age-related differences in the distribution pattern of tendon fibril thickness and in the expression of the tendon relevant genes collagen type 1 (Col1), Col3, Col5, tenascin-C, decorin, tenomodulin, versican, scleraxis and cartilage oligomeric matrix protein were investigated.
31792963	4	92	gly	oligomeric	801:810	arg1	the tendon relevant genes collagen type 1 (Col1)	cartilage oligomeric matrix protein			the tendon relevant genes collagen type 1 (Col1)	OGER		cartilage oligomeric matrix protein	P49747		Age-related differences in the distribution pattern of tendon fibril thickness and in the expression of the tendon relevant genes collagen type 1 (Col1), Col3, Col5, tenascin-C, decorin, tenomodulin, versican, scleraxis and cartilage oligomeric matrix protein were investigated.
29865036	6	51	gly	fucosylated	952:962	arg1	fucosylated N-/O-linked glycans				fucosylated N-/O-linked glycans						RESULTS A total of 9/9, 8/11, and 9/9 fucosylated N-/O-linked glycans were annotated in the isolated salivary proteins from HV, AG, and GC, respectively.
31196533	1	33	gly	used	222:225	arg2	A novel magnetic adsorbent genipin-crosslinked chitosan/graphene oxide-SO3H (GC/MGO-SO3H) composite			A novel magnetic adsorbent genipin-crosslinked chitosan/graphene oxide-SO3H (GC/MGO-SO3H) composite						composite	A novel magnetic adsorbent genipin-crosslinked chitosan/graphene oxide-SO3H (GC/MGO-SO3H) composite was prepared and used as adsorbents of environmental pollutant.
30309012	1	69	gly	database	153:160	arg1	sugars	database			sugars	Fterm		database			Due to a lack of a food composition database on starch and sugars, we developed a comprehensive database on starch and seven types of sugars in commonly consumed foods (n = 2222) in Japan.
30217822	9	71	gly	glycosylated	1415:1426	arg1	glycosylated full-length FH	glycosylated full-length FH				PUBTATOR		FH	3075		These two structures are the most accurate to date for glycosylated full-length FH.
29673153	3	13	gly	pectin	480:485	arg1	monosaccharide composition	pectin			monosaccharide composition	Fterm		pectin			The monosaccharide composition and rheological properties of the pectin were determined.
31409852	0	24	gly	Impact	0:5	arg1	human milk oligosaccharide composition	Impact			human milk oligosaccharide composition	OGER		Impact	Q9P2X3		Impact of maternal characteristics on human milk oligosaccharide composition over the first 4 months of lactation in a cohort of healthy European mothers.
29351237	8	8	gly	O-glycopeptide	1080:1093	arg2	two different O-glycopeptide sites			two different O-glycopeptide sites						O-glycopeptide sites	N-Glycopeptide analysis with UHPLC-QTOF-MSE confirmed N-glycosylation sites as well as two different O-glycopeptide sites.
29351237	8	71	gly	N-glycosylation	1033:1047	arg2	N-glycosylation sites			N-glycosylation sites						sites	N-Glycopeptide analysis with UHPLC-QTOF-MSE confirmed N-glycosylation sites as well as two different O-glycopeptide sites.
29530027	7	19	gly	isolated	1002:1009	arg2	KGF AND polysaccharide fractions	KGF			polysaccharide fractions	PUBTATOR		KGF	2252		METHODS Firstly, the composition of polysaccharide fractions isolated from K. grandifoliola stem bark (KGF), C. sanguinolenta (CSF) and C. citratus (CCF) leaves was assessed.
31687435	5	44	gly	glycoproteins	993:1005	arg1	hepatic glycoproteins	hepatic glycoproteins				Fterm		glycoproteins			These structural alterations of hepatic glycoproteins were not correlated with the expression levels of glycosyltransferase genes but were correlated with down-regulated expression of the Gale gene, which encodes a rate-limiting enzyme for the synthesis of sugar nucleotide donors for protein glycosylation in the liver.
30977264	5	60	gly	pro-angiogenic	650:663	arg1	a pro-angiogenic glycosaminoglycan			pro	a pro-angiogenic glycosaminoglycan					pro	Membranes were treated in a layer-by-layer approach to develop highly charged electrostatic layer that could bind heparin as a pro-angiogenic glycosaminoglycan.
30626008	13	52	gly	8-amino-3,8-dideoxy-manno-oct-2-ulosonic	1353:1392	arg1	Kdo8N	oct-2			Kdo8N	OGER		oct-2	O15244		The oligosaccharide was characterized by the presence of a residue of 8-amino-3,8-dideoxy-manno-oct-2-ulosonic acid (Kdo8N) and of a d,d-heptose, with both residues being identified in other oligosaccharides from Shewanella species.
30729136	6	41	gly	glycosylated	1008:1019	arg2	the same sites	protein		sites		Fterm		protein		sites	Analysis of the N-linked glycans using mass spectrometry revealed that the H1 protein is glycosylated at the same sites as the native HA.
29385801	3	38	gly	sialylated	517:526	arg1	the sialylated milk oligosaccharides				the sialylated milk oligosaccharides						A detailed knowledge of the structures, compositions, and quantities of the sialylated milk oligosaccharides (SMOs) is a prerequisite for understanding their biological roles.
32009786	3	61	gly	used	532:535	arg2	Alg-CS composite			Alg-CS composite						composite	Alg-CS composite was first used to load flurbiprofen (Flu), which is a kind of anti-inflammatory non-steroidal molecule.
30218302	3	35	gly	pectin	473:478	arg1	galacturonic acid content	pectin			galacturonic acid content	Fterm		pectin			Compared with mineral acid-extracted pectin, the yield, molecular weight, galacturonic acid content, and DE of the AA-extracted pectin were higher while neutral sugars were lower.
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND arabinose	The extracted low-methoxyl pectin			arabinose	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND mannose	The extracted low-methoxyl pectin			mannose	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND neutral monosaccharides	The extracted low-methoxyl pectin			neutral monosaccharides	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND glucose	The extracted low-methoxyl pectin			glucose	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND galactose	The extracted low-methoxyl pectin			galactose	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND fucose	The extracted low-methoxyl pectin			fucose	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
31320048	4	4	gly	contained	1023:1031	arg1	The extracted low-methoxyl pectin AND rhamnose	The extracted low-methoxyl pectin			rhamnose	Fterm		pectin			The extracted low-methoxyl pectin (DE = 33.65%) with high lightness contained considerable amounts of uronic acids and neutral monosaccharides (glucose, fucose, arabinose, galactose, rhamnose, and mannose).
29644514	5	26	gly	1[Hex	1112:1116	arg1	The monosaccharide compositions	Hex			The monosaccharide compositions	OGER		Hex			The monosaccharide compositions of two of the acidic oligosaccharides were [Neu5Ac]1[Hex]6[HexNAc]4[deoxy Hex]2, while those of another two were [Neu5Ac]1[Hex]8[HexNAc]6[deoxy Hex]3.
31760000	7	55	gly	used	1279:1282	arg2	this composite			this composite						composite	The results indicate that this composite can be used as a potential adsorbent for treatment of water containing harmful substances.
31581071	3	73	gly	glycoprotein	487:498	arg1	glycan	glycoprotein			glycan	Fterm		glycoprotein			Epitope and glycan are two structure features of a glycoprotein.
31279100	5	13	gly	used	575:578	arg2	Three compositions			Three compositions						positions	Three compositions of 3D porous CA scaffolds (2, 4, and 6 wt%) were used to investigate the effect of scaffold stiffness on PCa cell response with PC-3, C4-2B, and 22Rv1 cell lines.
34123048	2	1	gly	sialylated	313:322	arg1	sialylated glycans				sialylated glycans						Precise determination of sialylated glycans, particularly their linkage isomers that can trigger distinct biological events and are indicative of different cancer types, remains a challenge, due to their complicated composition and limited structural differences.
31355147	3	55	gly	glycoproteins	579:591	arg1	lectin-mediated affinity capture glycoproteins	lectin-mediated affinity capture glycoproteins				Fterm		glycoproteins			Subsequently, lectin-mediated affinity capture glycoproteins, and MALDI-TOF/TOF-MS were employed to further acquire precise structural information of the altered glycans.
29865036	8	54	gly	fucosylated	1352:1362	arg1	fucosylated N-linked glycans				fucosylated N-linked glycans						The proportion of fucosylated N-linked glycans was decreased in GC (41.66%) compared with AG (43.63%) and HV (52.57%), as well as the fucosylated O-linked glycans was apparently decreased in GC (19.58%) compared with AG (25.43%) and HV (55.54%).
29865036	8	102	gly	fucosylated	1468:1478	arg1	the fucosylated O-linked glycans				the fucosylated O-linked glycans						The proportion of fucosylated N-linked glycans was decreased in GC (41.66%) compared with AG (43.63%) and HV (52.57%), as well as the fucosylated O-linked glycans was apparently decreased in GC (19.58%) compared with AG (25.43%) and HV (55.54%).
31581071	1	43	gly	glycoproteins	244:256	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Sensitive and specific detection methods are critical to the detection of glycoproteins.
31117955	9	49	gly	composition	1425:1435	arg1	composition 2 Hex 1			position 2	composition 2 Hex 1					position 2	In Danish Jersey, a very strong QTL was detected for the OS with composition 2 Hex 1 HexNAc (isomer 1) on BTA11.
30444534	8	25	gly	used	1312:1315	arg2	synbiotic compositions			synbiotic compositions						positions	These extracts could be used as prebiotic, synbiotic compositions or novel food prototypes to treat dysbiosis associated with many diseases.
30708003	2	12	gly	utilized	411:418	arg2	The resulting composite			The resulting composite						composite	The resulting composite, was utilized as an efficient heterogeneous catalyst for promoting Sonogashira and Heck reactions in the absence of any ligand and co-catalyst under mild reaction condition.
30258536	4	23	gly	domain	906:911	arg1	rare N-glycans			domain	rare N-glycans					domain	We describe a novel synthetic approach to the human IgG1 Fc peptide having a bisected decasaccharide and its nonbisected counterpart compound, the signatures of antibodies involving Fc domain with rare N-glycans expected to show much higher ADCC/CDC than abundant IgG N-glycans, and their application to the SRM-based quantitative glycoproteomics.
30258536	4	64	gly	having	789:794	arg1	the human IgG1 Fc peptide AND a bisected decasaccharide and its nonbisected counterpart compound			the human IgG1 Fc peptide	a bisected decasaccharide and its nonbisected counterpart compound					peptide	We describe a novel synthetic approach to the human IgG1 Fc peptide having a bisected decasaccharide and its nonbisected counterpart compound, the signatures of antibodies involving Fc domain with rare N-glycans expected to show much higher ADCC/CDC than abundant IgG N-glycans, and their application to the SRM-based quantitative glycoproteomics.
29432186	8	18	gly	N-glycosylation	1014:1028	arg2	N-glycosylation sites			N-glycosylation sites						sites	By analyzing B-cell repertoires by next-generation sequencing, we demonstrate that N-glycosylation sites are introduced at positions in which glycans can affect antigen binding as a result of a specific clustering of progenitor glycosylation sites in the germline sequences of variable domain genes.
29432186	8	44	gly	glycosylation	1159:1171	arg2	progenitor glycosylation sites			progenitor glycosylation sites						sites	By analyzing B-cell repertoires by next-generation sequencing, we demonstrate that N-glycosylation sites are introduced at positions in which glycans can affect antigen binding as a result of a specific clustering of progenitor glycosylation sites in the germline sequences of variable domain genes.
30648841	6	4	gly	P-glycoprotein	1011:1024	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		Subsequently, the inner cores of the nanoparticles sustainedly release their cargos in drug-resistant tumor cells to keep the effective drug concentration against the drug efflux mediated by P-glycoprotein.
31687435	0	22	gly	glycoproteins	69:81	arg1	hepatic glycoproteins	hepatic glycoproteins				Fterm		glycoproteins			Data set for characterization of the glycosylation status of hepatic glycoproteins in mice fed a low-carbohydrate ketogenic diet.
31687435	0	74	gly	glycosylation	37:49	arg1	hepatic glycoproteins	hepatic glycoproteins				Fterm		glycoproteins			Data set for characterization of the glycosylation status of hepatic glycoproteins in mice fed a low-carbohydrate ketogenic diet.
30258536	0	85	gly	Nonfucosylated	61:74	arg1	Scarce Nonfucosylated IgG Fc N-Glycans				Scarce Nonfucosylated IgG Fc N-Glycans						Synthetic Glycopeptides Allow for the Quantitation of Scarce Nonfucosylated IgG Fc N-Glycans of Therapeutic Antibody.
31636638	2	106	gly	glycoproteins	351:363	arg1	membrane-bound glycoproteins	membrane-bound glycoproteins				Fterm		glycoproteins			Composed of membrane-bound glycoproteins, sulfated proteoglycans and glycosaminoglycan side-chains, this structure is particularly essential for blood vascular barrier functions and leukocyte diapedesis.
29351237	4	3	gly	O-glycosylated	609:622	arg1	Ser52			Ser52 and Ser60				Factor VIIa		Ser52 and Ser60	The first ten glutamic acids of the N-terminal moiety are γ-carboxylated, Asn145 and Asn322 are N-glycosylated, and Ser52 and Ser60 are O-glycosylated.
29351237	4	21	gly	N-glycosylated	569:582	arg1	Asn322			Asn145 and Asn322				Factor VIIa		Asn145 and Asn322	The first ten glutamic acids of the N-terminal moiety are γ-carboxylated, Asn145 and Asn322 are N-glycosylated, and Ser52 and Ser60 are O-glycosylated.
31687435	2	2	gly	glycoproteins	443:455	arg1	hepatic glycoproteins	hepatic glycoproteins				Fterm		glycoproteins			The present article provides additional structural analysis data for the characterization of hepatic glycoproteins in mice fed a low-carbohydrate ketogenic diet (LCKD).
30776442	11	41	gly	used	1400:1403	arg2	the as-prepared CNF/AgNP composite			the as-prepared CNF/AgNP composite						composite	These results suggest that the as-prepared CNF/AgNP composite could potentially be used as an antimicrobial material in active food packaging systems.
31181275	7	55	gly	pectin	1341:1346	arg1	monosaccharide composition	pectin			monosaccharide composition	Fterm		pectin			FTIR spectroscopy and HPLC photodiode array detector revealed that conventional and novel extraction technologies do not change the chemical structure and monosaccharide composition of pectin significantly.
35518704	0	40	gly	O-glycosylation	12:26	arg1	modified N-linked oligosaccharide (Man12GlcNAc2∼Man16GlcNAc2) Pichia pastoris				modified N-linked oligosaccharide (Man12GlcNAc2∼Man16GlcNAc2) Pichia pastoris						Engineering O-glycosylation in modified N-linked oligosaccharide (Man12GlcNAc2∼Man16GlcNAc2) Pichia pastoris strains.
30258536	6	30	gly	glycopeptides	1605:1617	arg2	the synthetic Fc glycopeptides			the synthetic Fc glycopeptides						glycopeptides	Strikingly, SRM assay using the synthetic Fc glycopeptides as calibration standards uncovered the occurrence of the targeted IgG1 Fc fragment carrying a nonfucosylated and bisected (315 fmol, 0.20%) and its nonbisected counterpart (1154 fmol, 0.73%) in the tryptic digests from 158 pmol of anticancer antibody Herceptin (trastuzumab).
31422531	12	4	gly	used	2016:2019	arg2	Chitosan/ZnO NPs composite			Chitosan/ZnO NPs composite						composite	Chitosan/ZnO NPs composite can be used in any biosecurity program of poultry farms as an alternative to ineffective antimicrobial agents.
29644514	3	40	gly	Gal	605:607	arg1	Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)	Gal			Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)	OGER		Gal	Q8N6F7		The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose).
29644514	3	40	gly	Gal	605:607	arg1	β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)	Gal			β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)	OGER		Gal	Q8N6F7		The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose).
29644514	3	54	gly	Gal	626:628	arg1	Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)	Gal			Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)	OGER		Gal	Q8N6F7		The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose).
29644514	3	54	gly	Gal	626:628	arg1	β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)	Gal			β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)	OGER		Gal	Q8N6F7		The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose).
29644514	3	63	gly	Gal	562:564	arg1	Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)	Gal			Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)	OGER		Gal	Q8N6F7		The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose).
29644514	3	63	gly	Gal	562:564	arg1	β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)	Gal			β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)	OGER		Gal	Q8N6F7		The structures of the four neutral milk oligosaccharides were Fuc(α1-2)Gal(β1-4)Glc (2'-fucosyllactose), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (lacto-N-fucopentaose IV), Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)GlcNAc(β1-3)Gal(β1-4)Glc (fucosyl para lacto-N-neohexaose) and Fuc(α1-2)Gal(β1-4)GlcNAc(β1-3)[Fuc(α1-2)Gal(β1-4)GlcNAc(β1-6)]Gal(β1-4)Glc (difucosyl lacto-N-neohexaose).
30199712	3	44	gly	utilized	412:419	arg2	This composite			This composite						composite	This composite was utilized for enhancement of the conductivity of the immunosensor.
30258536	3	31	gly	glycopeptides	529:541	arg2	tryptic IgG Fc glycopeptides			tryptic IgG Fc glycopeptides						glycopeptides	The present study communicates that selected reaction monitoring (SRM)-based assay of tryptic IgG Fc glycopeptides is a promising approach for the characterization of antibodies when combined with structure-defined synthetic Fc peptides having a focused N-glycoform as a calibration standard.
30910957	2	35	gly	glycoproteins	261:273	arg1	Mucin-domain glycoproteins	Mucin-domain glycoproteins				Fterm		glycoproteins			Mucin-domain glycoproteins are known to be key players in a host of human diseases, especially cancer, wherein mucin expression and glycosylation patterns are altered.
31307013	3	10	gly	glycopeptide	647:658	arg2	glycopeptide			glycopeptide						glycopeptide	METHODS AND SUBJECTS Molecular biological, biochemical and glycopeptide analyses were used to examine how N-glycosylation at specific sites, including at N347 within the RCL, affect CBG ELISA or steroid-binding capacity assay (BCA) measurements.
31307013	3	58	gly	N-glycosylation	694:708	arg1	at N347			N347				corticosteroid-binding globulin	866	N347	METHODS AND SUBJECTS Molecular biological, biochemical and glycopeptide analyses were used to examine how N-glycosylation at specific sites, including at N347 within the RCL, affect CBG ELISA or steroid-binding capacity assay (BCA) measurements.
31307013	3	58	gly	N-glycosylation	694:708	arg1	specific sites			sites						sites	METHODS AND SUBJECTS Molecular biological, biochemical and glycopeptide analyses were used to examine how N-glycosylation at specific sites, including at N347 within the RCL, affect CBG ELISA or steroid-binding capacity assay (BCA) measurements.
30001603	3	51	gly	11.7:5.4:3.2:1.0	440:455	arg1	a Gal:Ara:Rha:GlcA ratio	2:1			a Gal:Ara:Rha:GlcA ratio	OGER		2:1	P35326		This monosaccharide composition was found similar to that of a commercial Arabic gum which exhibited a Gal:Ara:Rha:GlcA ratio of 11.7:5.4:3.2:1.0.
31770560	7	8	gly	used	1167:1170	arg2	these composites			these composites						composites	The good mechanical properties, water resistance and antimicrobial activity against pathogens recommend these composites to be used in the manufacture of packaging materials.
30997002	5	7	gly	deglycosylated	905:918	arg1	the fully deglycosylated protein	the fully deglycosylated protein				Fterm		protein			Hydrogen/deuterium exchange mass spectrometry (HDX-MS) data support this, with lower global deuterium uptake in solution when comparing intact to the fully deglycosylated protein.
31016304	10	64	gly	enoxaparin	1577:1586	arg1	The disaccharide composition	enoxaparin			The disaccharide composition	Fterm		enoxaparin			The disaccharide composition, sequence and the variety of glycans of an enoxaparin are more related to its AT binding-based anticoagulant activity.
31016304	10	64	gly	enoxaparin	1577:1586	arg1	glycans	enoxaparin			glycans	Fterm		enoxaparin			The disaccharide composition, sequence and the variety of glycans of an enoxaparin are more related to its AT binding-based anticoagulant activity.
31419551	2	2	gly	ALP	421:423	arg1	monosaccharide composition	ALP			monosaccharide composition	OGER		ALP	Q7L266		Analysis of monosaccharide composition and structure of one fraction from ALP (ALPN) were analyzed by High Performance Liquid Chromatography (HPLC) and Fourier Transform Infrared Spectoscopy (FT-IR).
31419551	2	28	gly	composition	374:384	arg1	ALPN	ALPN			composition	Cterm		ALPN	Q7L266		Analysis of monosaccharide composition and structure of one fraction from ALP (ALPN) were analyzed by High Performance Liquid Chromatography (HPLC) and Fourier Transform Infrared Spectoscopy (FT-IR).
31419551	2	28	gly	composition	374:384	arg1	ALP	ALP			composition	OGER		ALP	Q7L266		Analysis of monosaccharide composition and structure of one fraction from ALP (ALPN) were analyzed by High Performance Liquid Chromatography (HPLC) and Fourier Transform Infrared Spectoscopy (FT-IR).
31739031	4	22	gly	galactose	528:536	arg1	The SLP pectin	pectin			galactose	Fterm		pectin			The SLP pectin was rich in galacturonic acid and galactose (87.2 mol%), high in molecular weight (615.836 kDa) and low in degree of esterification (1.2-35.1%).
31739031	4	30	gly	acid	519:522	arg1	The SLP pectin	pectin			acid	Fterm		pectin			The SLP pectin was rich in galacturonic acid and galactose (87.2 mol%), high in molecular weight (615.836 kDa) and low in degree of esterification (1.2-35.1%).
29865036	7	8	gly	fucosylated	1246:1256	arg1	ten fucosylated O-linked glycans				ten fucosylated O-linked glycans						Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.
29865036	7	34	gly	fucosylated	1209:1219	arg1	five fucosylated N-linked glycans				five fucosylated N-linked glycans						Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.
29865036	7	92	gly	fucosylated	1085:1095	arg1	six fucosylated N-linked glycansand four O-linked glycans				six fucosylated N-linked glycansand four O-linked glycans						Among these, six fucosylated N-linked glycansand four O-linked glycans exhibited significantly increased expression levels in GC, while five fucosylated N-linked glycans and ten fucosylated O-linked glycans exhibited significantly decreased expression levels in GC.
31891214	0	114	gly	challenge	151:159	arg1	weaned pigs	pigs			challenge	OGER		pigs	Q96S52		Effects of chitosan nanoparticle supplementation on growth performance, humoral immunity, gut microbiota and immune responses after lipopolysaccharide challenge in weaned pigs.
31256371	7	26	gly	glycoproteins	1249:1261	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Such simple hydrazinolysis protocols should benefit not only the biotechnology industry but also academic laboratories for characterization of glycoproteins.
35518704	2	9	gly	O-mannosylated	343:356	arg1	yeast-specific O-mannosylated proteins	yeast-specific O-mannosylated proteins				Fterm		proteins			Both N- and O-linked oligosaccharides engineered yeast have been attractive prospects, since yeast-specific O-mannosylated proteins were reported to induce an aberrant immune response and alter pharmacokinetics in vivo.
29885215	2	1	gly	utilized	309:316	arg2	depsipeptides			depsipeptides						depsipeptides	Previous studies on depsipeptides utilized electrospray ionization ion mobility quadrupole time-of-flight (ESI-IM-QTOF) tandem mass spectrometry; such analysis was thorough yet time-consuming.
30138539	2	22	gly	proteins	353:360	arg1	important determinants	proteins			important determinants	Fterm		proteins			Irrespective of the dialysis modality, hemodialysis (HD) or peritoneal dialysis (PD), the amount and composition of proteins that are removed are important determinants of the biocompatibility of the therapy.
34123048	0	91	gly	sialylated	50:59	arg1	sialylated glycans				sialylated glycans						Biomimetic nanochannels for the discrimination of sialylated glycans via a tug-of-war between glycan binding and polymer shrinkage.
33463193	3	21	gly	used	422:425	arg2	a new chitosan/zinc oxide nanoparticle (CZNC) composite			a new chitosan/zinc oxide nanoparticle (CZNC) composite						composite	Recently, a new chitosan/zinc oxide nanoparticle (CZNC) composite has been used as a promising "green" biocide.
30910957	1	45	gly	O-glycosylated	137:150	arg1	Mucin domains			domains						domains	Mucin domains are densely O-glycosylated modular protein domains that are found in a wide variety of cell surface and secreted proteins.
30905597	0	63	gly	glycosylated	37:48	arg1	the activated leukocyte cell adhesion molecule	the activated leukocyte cell adhesion molecule				OGER		activated leukocyte cell adhesion molecule	Q61490		Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.
31256371	1	1	gly	glycoproteins	178:190	arg1	whole glycoproteins	whole glycoproteins				Fterm		glycoproteins			Analysis of carbohydrate structures is an integral part of understanding the structure-function relationship of glycans as well as whole glycoproteins.
29432186	4	30	gly	domain	517:522	arg1	variable domain glycans				variable domain glycans						High levels of variable domain glycans have been associated with autoantibodies in rheumatoid arthritis, as well as certain follicular lymphomas.
31028613	15	20	gly	fucosylated	2038:2048	arg1	fucosylated oligosaccharides				fucosylated oligosaccharides						These results could be explained if cytosolic xyloglucan α-fucosidases are the ancestral state in angiosperms, with fucosylated oligosaccharides transported across the plasma membrane.
31581071	6	1	gly	epitope	968:974	arg1	the peptide epitope and glycans-imprinted Raman-active silver nanoparticles				the peptide epitope and glycans-imprinted Raman-active silver nanoparticles						It relies on double recognition towards a target glycoprotein by two different types of MIPs, using epitope-imprinted gold nanoparticles (AuNPs)-coated slide as capturing substrate to recognize the peptide epitope and glycans-imprinted Raman-active silver nanoparticles as labeling nanotags to recognize the glycans.
31581071	6	42	gly	peptide	960:966	arg1	the peptide epitope				the peptide epitope						It relies on double recognition towards a target glycoprotein by two different types of MIPs, using epitope-imprinted gold nanoparticles (AuNPs)-coated slide as capturing substrate to recognize the peptide epitope and glycans-imprinted Raman-active silver nanoparticles as labeling nanotags to recognize the glycans.
31581071	6	65	gly	glycoprotein	811:822	arg1	a target glycoprotein	a target glycoprotein				Fterm		glycoprotein			It relies on double recognition towards a target glycoprotein by two different types of MIPs, using epitope-imprinted gold nanoparticles (AuNPs)-coated slide as capturing substrate to recognize the peptide epitope and glycans-imprinted Raman-active silver nanoparticles as labeling nanotags to recognize the glycans.
35518704	1	55	gly	glycoproteins	179:191	arg1	therapeutic glycoproteins	glycoproteins			humanized N-linked oligosaccharides	Fterm		glycoproteins			Yeast have been engineered for the production of therapeutic glycoproteins with humanized N-linked oligosaccharides.
30026097	1	9	gly	used	147:150	arg2	ε-Poly-l-lysine			ε-Poly-l-lysine						lysine	ε-Poly-l-lysine (ε-PL) is widely used as an antibacterial agent because of its broad antimicrobial spectrum.
31891214	1	38	gly	challenge	386:394	arg1	weaned pigs	pigs			challenge	OGER		pigs	Q96S52		In this study, we aimed to determine the effects of dietary supplementation with chitosan nanoparticles (CNP) on growth performance, immune status, gut microbiota and immune responses after lipopolysaccharide challenge in weaned pigs.
35518704	6	46	gly	glycoproteins	1261:1273	arg1	therapeutic glycoproteins	glycoproteins			engineered N-	Fterm		glycoproteins			Thus, by disrupting O-mannosyltransferase PMT1 in an N-glycosylation engineered Pichia pastoris strain, we generated an effective glycoengineered Pichia pastoris strain to effectively produce therapeutic glycoproteins with both engineered N- and O-linked oligosaccharides.
35518704	6	46	gly	glycoproteins	1261:1273	arg1	therapeutic glycoproteins	glycoproteins			O-linked oligosaccharides	Fterm		glycoproteins			Thus, by disrupting O-mannosyltransferase PMT1 in an N-glycosylation engineered Pichia pastoris strain, we generated an effective glycoengineered Pichia pastoris strain to effectively produce therapeutic glycoproteins with both engineered N- and O-linked oligosaccharides.
31687435	3	36	gly	glycoproteins	531:543	arg1	hepatic glycoproteins	hepatic glycoproteins				Fterm		glycoproteins			Analysis of hepatic glycoproteins by enzyme-linked assay using the lectins UEA-I, ConA, LCA, and WGA showed that the LCKD decreased mature forms of complex-type glycans but increased immature forms of glycans on glycoproteins.
31687435	3	41	gly	glycoproteins	723:735	arg1	glycoproteins	glycoproteins				Fterm		glycoproteins			Analysis of hepatic glycoproteins by enzyme-linked assay using the lectins UEA-I, ConA, LCA, and WGA showed that the LCKD decreased mature forms of complex-type glycans but increased immature forms of glycans on glycoproteins.
31687435	3	65	gly	glycans	712:718	arg1	glycoproteins	glycoproteins			glycans	Fterm		glycoproteins			Analysis of hepatic glycoproteins by enzyme-linked assay using the lectins UEA-I, ConA, LCA, and WGA showed that the LCKD decreased mature forms of complex-type glycans but increased immature forms of glycans on glycoproteins.
31820139	4	1	gly	used	528:531	arg2	A nanocomposite			A nanocomposite						nanocomposite	A nanocomposite consisting of graphene oxide and chitosan (GO-chit) was used to immobilize the aptamer via formation of an amide link.
31196533	6	4	gly	utilized	911:918	arg2	the GC/MGO-SO3H composite			the GC/MGO-SO3H composite						composite	This study has demonstrated that the GC/MGO-SO3H composite could be utilized as an efficient and with high speed.
31181275	4	61	gly	UMAE-pectin	698:708	arg1	the maximum galacturonic acid content	pectin			the maximum galacturonic acid content	Fterm		pectin			The UMAE-pectin with the maximum galacturonic acid content (76.85%) and molecular weight (6.91 × 103 kDa) presented the highest emulsifying activity (61.2-61.3%) and emulsion stability (94.3-95.2%) with a monomodal droplet size distribution at cold and ambient storage temperatures.
29432186	7	45	gly	domain	872:877	arg1	variable domain glycans				variable domain glycans						Our aim was to elucidate the role of variable domain glycans during antigen-specific antibody responses.